Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How might the phase II PARADIGM trial data impact treatment decisions for newly diagnosed fit adults with acute myeloid leukemia (AML)?

In this interview, Fathi discussed key findings from the open-label, randomized, phase II PARADIGM trial comparing azacitidine + venetoclax with conventional induction chemotherapy in functionally fit patients with newly diagnosed AML (NCT04801797). The primary endpoint was event-free survival.

This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.